Alto Neuroscience, Inc. (ANRO) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ANRO Insider Trading Activity
ANRO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $190,833 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Savitz Adam | CHIEF MEDICAL OFFICER | 2 | $190,833 | 0 | $0 | $190,833 |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Insider Activity of Alto Neuroscience, Inc.
Over the last 12 months, insiders at Alto Neuroscience, Inc. have bought $190,833 and sold $0 worth of Alto Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Alto Neuroscience, Inc. have bought $190,833 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Savitz Adam (CHIEF MEDICAL OFFICER) — $190,833.
The last purchase of 2,931 shares for transaction amount of $38,748 was made by Savitz Adam (CHIEF MEDICAL OFFICER) on 2024‑07‑10.
List of Insider Buy and Sell Transactions, Alto Neuroscience, Inc.
| 2024-07-10 | Savitz Adam | CHIEF MEDICAL OFFICER | 2,931 0.0326% | $13.22 | $38,748 | -65.94% | ||
| 2024-07-09 | Savitz Adam | CHIEF MEDICAL OFFICER | 12,069 0.1279% | $12.60 | $152,085 | -67.38% |
ANRO Institutional Investors: Active Positions
| Increased Positions | 46 | +59.74% | 7M | +32.26% |
| Decreased Positions | 31 | -40.26% | 7M | -31.8% |
| New Positions | 20 | New | 4M | New |
| Sold Out Positions | 18 | Sold Out | 5M | Sold Out |
| Total Postitions | 92 | +19.48% | 22M | +0.46% |
ANRO Ownership Change vs Market
Institutional Investor Ownership
| Alpha Wave Global, Lp | $9,047.00 | 13.73% | 3.71M | 0 | 0% | 2024-12-31 |
| Point72 Asset Management, L.P. | $4,129.00 | 6.27% | 1.69M | +714,461 | +73.08% | 2024-12-31 |
| Blackrock, Inc. | $3,560.00 | 5.4% | 1.46M | -20,838 | -1.41% | 2025-03-31 |
| Fmr Llc | $3,088.00 | 4.69% | 1.27M | -1M | -46.45% | 2024-12-31 |
| Vanguard Group Inc | $3,000.00 | 4.55% | 1.23M | -43,848 | -3.44% | 2024-12-31 |
| Franklin Resources Inc | $2,837.00 | 4.31% | 1.16M | -58,104 | -4.76% | 2024-12-31 |
| Citadel Advisors Llc | $2,381.00 | 3.62% | 975,986 | +975,986 | New | 2024-12-31 |
| Vestal Point Capital, Lp | $2,233.00 | 3.39% | 915,000 | +265,000 | +40.77% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $2,061.00 | 3.13% | 844,823 | +36,319 | +4.49% | 2024-12-31 |
| Marshall Wace, Llp | $2,043.00 | 3.1% | 837,374 | +837,374 | New | 2024-12-31 |